Frontline options commonly used to treat immune thrombocytopenia and variables that affect treatment selection.
Strategies and types of tests used by clinicians to help exclude various conditions that may present similarly to immune thrombocytopenia during a diagnostic work-up.
A discussion on the risks of bleeding episodes and venous thromboembolism associated with immune thrombocytopenia.
A description of what immune thrombocytopenia is and presenting factors that prompt providers to refer patients to be assessed by a specialist for the condition.
Considerations of biosimilars as a valuable asset to the health care system, the impact of the competition biosimilars have on biologics regarding price and rebates, and final thoughts.
A discussion on the pricing of biosimilars and factors that limit the cost-savings potential.
Common myths and misconceptions for biosimilars are explored.
The panel discusses patient awareness of biosimilar products and whether they provide supplemental patient education through patient information sheets.
Raising clinician awareness of using biosimilar products.
The scope of the clinical pharmacist is discussed in switching a patient over to a preferred biosimilar along with the role of specialty pharmacy.
A discussion on limiting the number of biosimilars available for the same product at an institution regarding inventory, fridge space, and safety.
The panel explores the appropriateness of switching from a biologic to a biosimilar through consideration of factors such as the curative vs noncurative setting, the EMR system, and patient education.